What would you like to look for?
Site search
31 January 2024

EraCal Therapeutics AG ("EraCal"), a Swiss biotech start-up company focusing on the fight of obesity, has licensed certain assets to Novo Nordisk for a total amount of EUR 235m in a collaboration and license deal. VISCHER advises EraCal on all legal issues related to the transaction.

The VISCHER team includes Christian Wyss (Partner, Corporate/M&A), Pauline Pfirter (Senior Associate, Corporate/M&A) and Lukas Wendt (Associate, Corporate/M&A).

Authors: Christian Wyss, Pauline Pfirter, Lukas Wendt